Skip to content
Screener

Cash & Equivalents at other companies

Merck & Co. logo
Merck & Co.MRK
$5.4B-38.2%
Phibro Animal Health logo
Phibro Animal HealthPAHC
$54.93M-9.0%
Zoetis logo
ZoetisZTS
$1.48B-9.6%
Neogen logo
NeogenNEOG
$159.9M+25.2%
Tractor Supply Company logo
Tractor Supply CompanyTSCO
$231.59M+2.6%
Central Garden & Pet Company logo
Central Garden & Pet CompanyCENT
$1.01B+39.1%

Other financials

Income statement

See full
Revenue$1.4B+10.2%
Gross profit$798.0M+11.9%
Net income$54.0M+391%
EPS (diluted)$0.11+450%

Balance sheet

See full
Total debt$4.2B-6.2%
Total equity$6.6B-2.8%
Total assets$13.6B-1.3%

Cash flow

See full
Operating cash flow$277.0M+16.9%
CapEx$33.0M-42.1%
Free cash flow$244.0M+35.6%

Valuation

See full
Market cap$13.1B+89.0%
Enterprise value$16.81B+54.0%
P/S2.6×+1.1×

Profitability

See full
Gross margin55.4%+0.6pp
Net margin-4%-13.8pp
FCF margin7.5%-0.5pp

Returns & leverage

See full
Return on equity-3%-9.9pp
Debt / equity0.6×0.0×
Current ratio2.1×-0.5×

Where this comes from

Reported directly by Elanco Animal Health Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The source filing: Elanco Animal Health Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 9:06 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001739104-26-000043
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Net Cash Used for Financing Activities(139)(104)
Effect of exchange rate changes on cash and cash equivalents456
Net (decrease) increase in cash and cash equivalents(15)71
Cash and cash equivalents – beginning of period545468
Cash and cash equivalents – end of period$530$539
Supplemental disclosure of non-cash investing and financing activities:
Right-of-use assets obtained in exchange for new finance lease liability$234
Consideration transferred in a business combination$167

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Elanco Animal Health Inc.'s cash & equivalents?
Elanco Animal Health Inc. (ELAN) reported cash & equivalents of $530M in Q2 2026.
How has Elanco Animal Health Inc.'s cash & equivalents changed year-over-year?
Elanco Animal Health Inc.'s cash & equivalents decreased by 1.7% year-over-year, from $539M to $530M.
What is the long-term trend for Elanco Animal Health Inc.'s cash & equivalents?
Over 5 years (2020 to 2025), Elanco Animal Health Inc.'s cash & equivalents has grown at a 1.5% compound annual growth rate (CAGR), from $506M to $545M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.

Ask your AI about Elanco Animal Health Inc.'s cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude